View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 29, 2020

Japan grants approval for GSK’s Duvroq to treat CKD-related anaemia

Japan's Ministry of Health, Labour and Welfare has granted the first regulatory approval for GlaxoSmithKline (GSK)'s Duvroq (daprodustat) to treat anaemia caused by chronic kidney disease (CKD).

Japan’s Ministry of Health, Labour and Welfare has granted the first regulatory approval for GlaxoSmithKline (GSK)’s Duvroq (daprodustat) to treat anaemia caused by chronic kidney disease (CKD).

Free Report
img

What is the Global Healthcare and Pharma Market Q2 Outlook?

Given the background of high inflation, re-emerging supply chain issues, and the widespread macro-economic implications of the Ukraine conflict, the global pharmaceutical industry is facing an entirely new set of challenges following the turbulence of the COVID-19 pandemic. GlobalData’s World Markets Healthcare (WMH) service has released its latest Q2 forecast. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies. However, the pharma sector is proving resilient, and we are projecting 4.4% global growth for the year ahead. Yet it remains that the current economic picture is inverting some baseline assumptions from previous quarterly forecasts and altering which markets we expect the key growth levers to derive from. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies.
by GlobalData
Enter your details here to receive your free Report.

Duvroq is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) intended to offer an oral alternative to injectable ESAs / recombinant human erythropoietin.

In CKD patients, anaemia develops because the kidneys no longer generate adequate amounts of erythropoietin, associated with red blood cell production.

HIF-PHIs induce the body’s adaptations to hypoxia and promote the bone marrow to produce more red blood cells, reducing anaemia.

GSK chief scientific officer and R&D president Dr Hal Barron said: “The approval of Duvroq brings a new, convenient oral treatment option to nearly 3.5 million patients in Japan who have anaemia associated with renal disease.

“We are pleased with this first approval and look forward to sharing data from our ongoing Phase III programme as we seek to help many more patients suffering with this disease around the world.”

The Japanese approval was mainly based on positive results from the Phase III programme conducted in the country. The trials assessed Duvroq to treat anaemia in patients with CKD from stages 3-5.

As part of the Phase III programme in Japan, a 52-week study enroled 271 haemodialysis patients who were on ESAs before entering the study. It compared daprodustat to darbepoetin alpha.

Another 52-week study involved 299 patients with stage 3-5 CKD who were not on dialysis, with or without prior use of ESA. This study compared daprodustat to epoetin beta pego, and included an arm of 56 patients on peritoneal dialysis treated with daprodustat.

In addition, a 24-week open-label haemodialysis study in 28 patients who were not on ESAs prior to the study treated all participants with daprodustat.

Two Phase III cardiovascular outcome studies, ASCEND-D and ASCEND-ND, are ongoing and expected to support global regulatory filings of the drug.

In April, GSK received the US Food and Drug Administration (FDA) approval for an expanded indication of its ovarian cancer drug Zejula.

Related Companies

Free Report
img

What is the Global Healthcare and Pharma Market Q2 Outlook?

Given the background of high inflation, re-emerging supply chain issues, and the widespread macro-economic implications of the Ukraine conflict, the global pharmaceutical industry is facing an entirely new set of challenges following the turbulence of the COVID-19 pandemic. GlobalData’s World Markets Healthcare (WMH) service has released its latest Q2 forecast. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies. However, the pharma sector is proving resilient, and we are projecting 4.4% global growth for the year ahead. Yet it remains that the current economic picture is inverting some baseline assumptions from previous quarterly forecasts and altering which markets we expect the key growth levers to derive from. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology